Truist initiated coverage of Beta Bionics (BBNX) with a Buy rating and $26 price target Beta Bionics is the newest U.S. pump entrant with an algorithm focusing on ease-of-use and simpler setup for both patients and clinicians with competitive outcomes, and the firm’s physician feedback suggests iLet and Beta Bionics’ focuses align with unmet needs around automation, reduced setup, and future glucagon/insulin delivery, the analyst tells investors in a research note. The firm sees Beta Bionics increasing U.S. share to 5%-6% by 2028 within a $3B U.S. pump market and fueling a 37%+ 2024-2028 revenue compound annual growth rate.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Beta Bionics assumed with a Buy at Lake Street
- Beta Bionics initiated with an Outperform at Wolfe Research
- Beta Bionics initiated with a Neutral at Goldman Sachs
- Positive Developments and Strategic Advancements Drive Buy Rating for Beta Bionics, Inc.
- Beta Bionics Q1 2025 Earnings: Strong Growth and Optimism